Immuno-Oncology Xchange West Coast 2018


Titles and Bullets
9:00am – 10:00am

The challenges of validating complex immune biomarkers for clinical trials
  • What are the most common I-O biomarkers implemented in clinical trials and what are the challenges/ considerations to validate them” fit for purpose”?
  • What level of oversight is needed for analyzing biospecimens and what are the required Trial Master File (TMF) documents?
  • How do we get the vendors to validate assays in disease representative, matrix specific, samples? How do we reduce vendor resistance to providing required TMF documents in appropriate submission ready format?

Director, Early Development & Translational Immuno-Oncology

12:00pm – 1:00pm

What are the differentiators between the various Antibody platforms?
  • Why do antibodies from animals dominate the commercial and clinical pipelines?
  • What drives the selection of an antibody technology?

Vice President
Biologics Technologies & Development

10:30am – 11:30am

Protein biomarkers for response to immunotherapy.
  • How to best identify predictive or early prognostic biomarkers of immune response in plasma?
  • How effective is using a proteome-wide approach to reveal immune system interaction with checkpoint inhibitors and the biology behind resistance?
  • Blood specific protein markers: does it offer great potential to overcome immune related adverse events (irAE) associated with immunotherapies?
  • Can we better understand the effects of mono versus combined treatment strategies based on early response plasma biomarkers?

Senior Principal Scientist, Immunotherapy
Olink Proteomics

12:00pm – 1:00pm

Developing predictive biomarkers for immunotherapies to identify mechanisms of resistance.
  • Summarise current in vitro and in vivo biomarkers currently being used in IO trials
  • Discuss the dynamics of IOT therapies, time to engagement, targeting of cancer cells, T-cells and other immunomodulating cells. When does T-cell influx occur? When does T-cell inhibition occur?
  • Is pseudo-progression an issue in IOT?
  • What are the top 3-5 biomarkers that should be used to help with evaluating of IOT therapy?

Chief Operating Officer

3:20pm – 4:20pm

Protein and metabolite quantitation for identifying and validating predictive biomarkers of patient response to cancer therapies.
  • Where do discovery proteomics and phosphoproteomics fit in the drug development pipeline?
  • What is the value of targeted precise protein quantitation, with isoform and phosphorylation information, for biomarker identification?
  • How can we use pathway-driven proteomics and metabolomics panels to identify treatment targets and mechanisms of resistance?
  • How do quantitative approaches help to avoid validation pitfalls?
  • Can high-specificity diagnostic assays for protein drug targets complement IHC-based approaches?

Chief Scientific Officer
MRM Proteomics

4:20pm – 5:20pm

Strategy of biomarker selection for predicting the efficacy of combining immunotherapy with targeted therapy.
  • Current potential biomarkers for checkpoint inhibitors
  • Mapping the MOA of the targeted therapy to the hallmarks of cancer
  • Assessment of in-scope technology platforms for biomarker discovery
  • Implementation of appropriate biomarker sample collection plans

Director, Clinical Biomarkers
Calithera Biosciences


Immuno-Oncology Xchange | West Coast 2018